TABLE 2.
Efficacies of QYL-438, QYL-769, and GCV against laboratory and clinical isolates of HCMV
| HCMV strain | EC50 (μM)a of:
|
||
|---|---|---|---|
| QYL-438 | QYL-769 | GCV | |
| AD169 (control) | 1.2 | 2.4 | 2.3 |
| Toledo (2)b | 8.6 ± 3.0 | 5.5 ± 1.3 | 9.8 ± 3.9 |
| Davis (2) | 2.5 ± 0.09 | 2.2 ± 0.62 | 5.3 ± 1.2 |
| Towne | 11.6 | 10.6 | 5.1 |
| EC (2) | 5.1 ± 4.3 | 2.2 ± 0.6 | 3.9 ± 0.8 |
| CH | 3.1 | 2.7 | 4.3 |
| Coffman (2) | 6.9 ± 6.0 | 3.1 ± 0.8 | 4.7 ± 0.6 |
| C8708/17-1-1 (3) | 9.4 ± 2.6 | 4.4 ± 3.3 | 5.9 ± 3.8 |
| C9208/3-3-1 | 6.9 | 2.2 | 4.7 |
| C9208/5-4-2 | 9.4 | 4.0 | 3.8 |
a
By PR assay. Some results are presented as means ± standard deviations.
b
Number of experiments shown in parentheses.